The Association of the British Pharmaceutical Industry (ABPI) published a long-awaited digital up-date in June that addressed the issue of tracking and reporting adverse events (AEs) online.
Previously, in April 2011, the Prescription Medicines Code of Practice Authority (PMCPA), which oversees the self-regulatory code of the ABPI, published "informal guidance" that included specific recommendations regarding the use of Twitter by pharmaceutical companies to promote medicines.
It doesn't seem that these efforts made much of an impression on industry insiders who were informally surveyed by Weber Shandwick, a leading global public relations firm.
This article reports the results of that survey, which includes advice for how to innovate online without waiting for more specific guidelines from regulators. As included are summaries of the guidelines mentioned above.
Topic headings include:
Read this article now. It's FREE...
- No Guidance, No Funding for Digital
- Everyone But Pharma Is Empowered Online
- Innovators Forge Ahead
- Pharma's Digital Dilemma
- Brits Beat FDA & PhRMA: Issue Social Media Guidance for Pharma
- The British Pharmaceutical Industry Issues Social Media Guidance for Adverse Event Reporting
Download PDF file